Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chiara Caparello

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Journal of Experimental & Clinical Cancer Research : CR|December 24, 2015
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published dataLorenzo Fornaro, Caterina Vivaldi, Stefano Cereda, et al.
Anti-Cancer Agents in Medicinal Chemistry|July 28, 2021
Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of OutcomesCarmelo Tibaldi, Francesca Mazzoni, Vieri Scotti, et al.
Cancer Biomarkers : Section a of Disease Markers|December 28, 2017
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomasIacopo Petrini, Monica Lencioni, Enrico Vasile, et al.
Journal of Hepatology|April 29, 2018
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trialRichard S Finn, Philippe Merle, Alessandro Granito, et al.
Tumori|May 10, 2018
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocolAndrea Casadei Gardini, Luca Faloppi, Giuseppe Aprile, et al.
Oncology Research|May 1, 2026
Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall SurvivalLuigi Coltelli, Paola Orlandi, Chiara Finale, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Journal of Experimental & Clinical Cancer Research : CR|December 24, 2015
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published dataLorenzo Fornaro, Caterina Vivaldi, Stefano Cereda, et al.
Anti-Cancer Agents in Medicinal Chemistry|July 28, 2021
Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of OutcomesCarmelo Tibaldi, Francesca Mazzoni, Vieri Scotti, et al.
Cancer Biomarkers : Section a of Disease Markers|December 28, 2017
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomasIacopo Petrini, Monica Lencioni, Enrico Vasile, et al.
Journal of Hepatology|April 29, 2018
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trialRichard S Finn, Philippe Merle, Alessandro Granito, et al.
Tumori|May 10, 2018
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocolAndrea Casadei Gardini, Luca Faloppi, Giuseppe Aprile, et al.
Oncology Research|May 1, 2026
Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall SurvivalLuigi Coltelli, Paola Orlandi, Chiara Finale, et al.
Pageof 3